IL143036A0 - Engineered cytotoxic ribonuclease - Google Patents

Engineered cytotoxic ribonuclease

Info

Publication number
IL143036A0
IL143036A0 IL14303699A IL14303699A IL143036A0 IL 143036 A0 IL143036 A0 IL 143036A0 IL 14303699 A IL14303699 A IL 14303699A IL 14303699 A IL14303699 A IL 14303699A IL 143036 A0 IL143036 A0 IL 143036A0
Authority
IL
Israel
Prior art keywords
engineered cytotoxic
cytotoxic ribonuclease
ribonuclease
engineered
cytotoxic
Prior art date
Application number
IL14303699A
Other languages
English (en)
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of IL143036A0 publication Critical patent/IL143036A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
IL14303699A 1998-11-24 1999-11-22 Engineered cytotoxic ribonuclease IL143036A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/199,242 US6280991B1 (en) 1997-10-15 1998-11-24 Engineered cytotoxic ribonclease
PCT/US1999/027670 WO2000031242A2 (en) 1998-11-24 1999-11-22 Engineered cytotoxic ribonuclease

Publications (1)

Publication Number Publication Date
IL143036A0 true IL143036A0 (en) 2002-04-21

Family

ID=22736771

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14303699A IL143036A0 (en) 1998-11-24 1999-11-22 Engineered cytotoxic ribonuclease
IL143036A IL143036A (en) 1998-11-24 2001-05-08 Engineered cytotoxic ribonuclease

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143036A IL143036A (en) 1998-11-24 2001-05-08 Engineered cytotoxic ribonuclease

Country Status (7)

Country Link
US (1) US6280991B1 (https=)
EP (1) EP1131417A2 (https=)
JP (2) JP4731015B2 (https=)
AU (1) AU778024B2 (https=)
CA (1) CA2351735C (https=)
IL (2) IL143036A0 (https=)
WO (1) WO2000031242A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2489446A1 (en) * 2002-06-14 2003-12-24 Wisconsin Alumni Research Foundation Ribonuclease zymogen design
WO2004085611A2 (en) * 2003-03-21 2004-10-07 The Research Foundation Of State University Of New York Model for mutually exclusive domain folding molecular switch
WO2005115477A2 (en) 2004-04-13 2005-12-08 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
CA2604243C (en) 2004-04-14 2015-11-24 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7655757B2 (en) * 2005-06-16 2010-02-02 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants
WO2006138458A1 (en) * 2005-06-16 2006-12-28 Wisconsin Alumni Research Foundation Cytotoxic ribonuclease variants
WO2007041361A1 (en) * 2005-09-30 2007-04-12 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Modified recombinant anti-tumor rnase
EP2044097A4 (en) * 2006-06-23 2010-10-06 Quintessence Biosciences Inc Modified ribonucleases
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
US8069251B2 (en) * 2007-06-01 2011-11-29 Adobe Systems Incorporated System and/or method for client-driven server load distribution
EP2205271B1 (en) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
WO2009088992A2 (en) * 2008-01-07 2009-07-16 University Of Vermont And State Agricultural College Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
US8029782B2 (en) 2008-10-01 2011-10-04 Quintessence Biosciences, Inc. Therapeutic ribonucleases
KR101934923B1 (ko) 2009-11-02 2019-04-10 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료학적 뉴클레아제 조성물 및 방법
PH12013502441B1 (en) 2011-04-29 2019-02-08 Univ Washington Therapeutic nuclease compositions and methods
PL3063275T3 (pl) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Terapeutyczne fuzje nukleaza-albumina i sposoby
ES2971441T3 (es) * 2016-05-06 2024-06-05 Biodynamic Res Foundation Composición farmacéutica que contiene un fármaco macromolecular
JP7308034B2 (ja) 2016-07-01 2023-07-13 リゾルブ セラピューティクス， エルエルシー 最適化二重ヌクレアーゼ融合物および方法
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
US11286469B2 (en) 2017-11-09 2022-03-29 Wisconsin Alumni Research Foundation Combination chemotherapy for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840840A (en) 1990-04-17 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Selective RNase cytotoxic reagents
US5389537A (en) 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity
US5840296A (en) * 1997-10-15 1998-11-24 Raines; Ronald T. Engineered cytotoxic ribonuclease A

Also Published As

Publication number Publication date
JP2002532067A (ja) 2002-10-02
CA2351735C (en) 2011-09-13
JP2011078428A (ja) 2011-04-21
WO2000031242A2 (en) 2000-06-02
AU778024B2 (en) 2004-11-11
JP4731015B2 (ja) 2011-07-20
US6280991B1 (en) 2001-08-28
CA2351735A1 (en) 2000-06-02
AU1918400A (en) 2000-06-13
IL143036A (en) 2009-06-15
WO2000031242A3 (en) 2000-11-23
EP1131417A2 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
IL143036A0 (en) Engineered cytotoxic ribonuclease
GB9825651D0 (en) Actuator
GB0204971D0 (en) No title
HUP9904224A3 (en) Form separeting materials
GB9911148D0 (en) Actuator
EP1143168A4 (en) ACTUATOR
IL137457A0 (en) Granulator
GB2370030B (en) Linear actuator
TW499033U (en) Electro-megnatic actuator
GB2350659B (en) Actuator
GB2344402B (en) Actuator
HUP0102932A3 (en) Bioreductive cytotoxic agents
PL354756A1 (en) Durable metallic materials
EP1087900A4 (en) PERFECTED PALLETIZER
GB9909904D0 (en) No title
HUP0104899A3 (en) Solid-state material
GB9911526D0 (en) Actuator
DE69940886D1 (en) Hiv impfstoff
SG86427A1 (en) Multi-diaphragm actuator
GB0008828D0 (en) No title
GB2347556B (en) Piezoelectric actor
GB9820883D0 (en) Syringe
GB9805090D0 (en) Aminopyridines
GB9929669D0 (en) Engineering
GB9820360D0 (en) Syringes